Physician profile
Adele M Whitted
NPI 1548693724
$7,522.17
in general payments reported to CMS, 2019-2025
25 companies · $3,314 in 2025
The $3,314 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,166 · 2022: $889 · 2023: $804 · 2024: $1,349 · 2025: $3,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863 · Travel and Lodging: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.91 |
| Travel and Lodging | $1,603.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,631.96 | 2025 | Watchman, Watchman Flx |
| Medtronic, INC. | $1,075.36 | 2025 | Symplicity G3 |
| Recor Medical INC | $953.30 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $677.96 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $638.53 | 2021-2025 | Lifevest |
| Amgen INC. | $467.82 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $302.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $272.25 | 2021-2025 | |
| Edwards Lifesciences Corporation | $260.74 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $236.16 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $215.96 | 2023-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $203.84 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $122.68 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $99.14 | 2021-2024 | Farxiga, Brilinta |
| Amarin Pharma, INC. | $59.28 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.33 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $44.05 | 2023 | Inpefa |
| Vifor Pharma, INC. | $41.44 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $40.39 | 2024 | Evkeeza |
| Biosense Webster, INC. | $32.00 | 2021 | |
| Galderma Laboratories, L.P. | $25.31 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.97 | 2024 | Arcalyst |
| Amryt Pharma Holdings Ltd | $16.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adele Whitted listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.